Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 10/20 | 0.43 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30989968 | 0.91 | HPGD (0.34) | PTGER4PTGER2MAPK1 | |
| SCHEMBL30989829 | 0.91 | HPGD (0.34) | PTGER4PTGER2MAPK1 | |
| SCHEMBL30990044 | 0.80 | MAPK1 (0.41) | PTGER4PTGER2MAPK1 | |
| SCHEMBL30989873 | 0.80 | MAPK1 (0.41) | PTGER4PTGER2MAPK1 | |
| SCHEMBL30989923 | 0.80 | ALDH1A1 (0.47) | PTGER4PTGER2 | |
| SCHEMBL30843152 | 0.74 | GPBAR1 (0.38) | PTGER4PTGER2SCN9A | |
| SCHEMBL30989874 | 0.74 | MEN1 (0.36) | PTGER4MAPK1 | |
| SCHEMBL30989872 | 0.74 | MEN1 (0.36) | PTGER4MAPK1 | |
| SCHEMBL30989808 | 0.72 | HTT (0.39) | PTGER4PTGER2SCN9A | |
| SCHEMBL30990036 | 0.69 | MAPT (0.36) | PTGER4PTGER2SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4612131-A1 | NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY | Cerevance, Inc. (US) | 2025-09-10 | — | — | EP | claimed |
| WO-2024095003-A1 | NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY | Cerevance, Inc. (US) | 2024-05-10 | — | — | WO | claimed |
| EP-4612131-A1 | NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY | Cerevance, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| WO-2024095003-A1 | NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY | Cerevance, Inc. (US) | 2024-05-10 | — | — | WO | disclosed |